RT Journal Article
T1 Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study.
A1 Alcaraz, Antonio
A1 Gacci, Mauro
A1 Ficarra, Vincenzo
A1 Medina-Polo, José
A1 Salonia, Andrea
A1 Fernández-Gómez, Jesús M
A1 Ciudin, Alexandru
A1 Castro-Díaz, David
A1 Rodríguez-Antolín, Alfredo
A1 Carballido-Rodríguez, Joaquín
A1 Cózar-Olmo, José M
A1 Búcar-Terrades, Santiago
A1 Pérez-León, Noemí
A1 Brenes-Bermúdez, Francisco J
A1 Molero-García, José M
A1 Ledesma, Antonio Fernández-Pro
A1 Herdman, Michael
A1 Manasanch, José
A1 Angulo, Javier C
A1 Group, On Behalf Of The Qualiprost Study
K1 BPH
K1 adverse effects
K1 hexanic extract of Serenoa repens
K1 moderate-severe LUTS
K1 quality of life
K1 sexual function
K1 tolerability
K1 watchful waiting
AB We investigated changes in symptoms and quality of life (QoL) in men with moderate-to-severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) receiving the hexanic extract of Serenoa repens (HESr) and compared results with a matched group on watchful waiting (WW). Data was from a real-world, open-label, prospective, multicenter study. This sub-group analysis included patients with moderate-to-severe symptoms receiving either the HESr 320 mg/daily for six months (HESr) or who remained untreated for LUTS/BPH (WW). Changes in urinary symptoms and QoL were measured by IPSS and BII questionnaires. Two statistical approaches (iterative matching and propensity score pairing) were used to maximize between-group comparability at baseline. Tolerability was assessed in the HESr group. After iterative matching, data for analysis was available for 783 patients (102 WW, 681 HESr). IPSS scores improved by a mean (SD) of 3.8 (4.4) points in the HESr group and by 2.2 (4.5) points in the WW group (p = 0.002). Changes in BII score were 1.8 (2.4) points and 1.0 (2.2) points, respectively (p
SN 2077-0383
YR 2022
FD 2022-02-12
LK http://hdl.handle.net/10668/21238
UL http://hdl.handle.net/10668/21238
LA en
DS RISalud
RD Apr 17, 2025